Bioventix plc
(“Bioventix” or the “Company”)
Interim dividend
confirmation
Bioventix plc (BVXP) (“Bioventix” or “the Company”), a UK
company specialising in the development and commercial supply of
high-affinity monoclonal antibodies for applications in clinical
diagnostics, announces that the Board has confirmed a cash interim
dividend of 52p per ordinary share, which will be paid on
22 April 2022.
The dividend timetable dates are below:
| Ex-dividend date: |
7 April 2022 |
| Record date: |
8 April 2022 |
| Payment date: |
22 April 2022 |
For further information please contact:
Bioventix plc
Peter Harrison
Chief Executive Officer Tel: 01252 728 001
finnCap Ltd
Geoff Nash/Simon Hicks
Alice Lane
Corporate Finance
ECM Tel: 020 7220 0500
About Bioventix plc:
Bioventix (www.bioventix.com) specialises in the development and
commercial supply of high-affinity monoclonal antibodies with a
primary focus on their application in clinical diagnostics, such as
in automated immunoassays used in blood testing. The antibodies
created at Bioventix are generated in sheep and are of particular
benefit where the target is present at low concentration and where
conventional monoclonal or polyclonal antibodies have failed to
produce a suitable reagent. Bioventix currently offers a portfolio
of antibodies to customers for both commercial use and R&D
purposes, for the diagnosis or monitoring of a broad range of
conditions, including heart disease, cancer, fertility, thyroid
function and drug abuse. Bioventix currently supplies antibody
products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its
shares are traded on AIM under the symbol BVXP.
